Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2011 1
2012 4
2013 3
2014 4
2015 3
2016 6
2017 6
2018 4
2019 9
2020 5
2021 11
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Gastric neuroendocrine tumor G2"
Page 1
Therapeutic Challenges for Gastric Neuroendocrine Neoplasms: Take It or Leave It?
Cavalcoli F, Gallo C, Coltro LA, Rausa E, Cantù P, Invernizzi P, Massironi S. Cavalcoli F, et al. Medicina (Kaunas). 2023 Oct 1;59(10):1757. doi: 10.3390/medicina59101757. Medicina (Kaunas). 2023. PMID: 37893475 Free PMC article. Review.
Background and Objectives: Gastric neuroendocrine neoplasms (gNENs) represent rare but increasingly recognized tumors. They are distinguished into three main clinical types (type-1, type-2, and type-3) according to gastrin level and at histological evaluation …
Background and Objectives: Gastric neuroendocrine neoplasms (gNENs) represent rare but increasingly recognized tumors. …
Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms.
Werner W, Detjen K, Bruneau A, Lurje I, Nestel N, Jann H, Tacke F, Wiedenmann B, Roderburg C, Hammerich L. Werner W, et al. Endocr Relat Cancer. 2023 Jun 2;30(7):e220357. doi: 10.1530/ERC-22-0357. Print 2023 Jul 1. Endocr Relat Cancer. 2023. PMID: 37130269
Clinical management of gastroenteropancreatic neuroendocrine neoplasms remains challenging. We recently introduced the FMS-like tyrosine kinase 3 ligand (FLT3LG) as a possible biomarker for a proinflammatory tumor microenvironment. Here, we put a spotlight on the qu …
Clinical management of gastroenteropancreatic neuroendocrine neoplasms remains challenging. We recently introduced the FMS-like tyros …
Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK. Del Rivero J, et al. J Clin Oncol. 2023 Nov 10;41(32):5049-5067. doi: 10.1200/JCO.23.01529. Epub 2023 Sep 29. J Clin Oncol. 2023. PMID: 37774329
PURPOSE: To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). METHODS: ASCO convened an Expert Panel to conduct a systematic review of relevant studie …
PURPOSE: To develop recommendations for systemic therapy for well-differentiated grade 1 (G1) to grade 3 (G3) metastatic gastroenteropancrea …
Recurrence and metastatic potential in Type 1 gastric neuroendocrine neoplasms.
Daskalakis K, Tsoli M, Karapanagioti A, Chrysochoou M, Thomas D, Sougioultzis S, Karoumpalis I, Kaltsas GA, Alexandraki KI. Daskalakis K, et al. Clin Endocrinol (Oxf). 2019 Oct;91(4):534-543. doi: 10.1111/cen.14055. Epub 2019 Jul 7. Clin Endocrinol (Oxf). 2019. PMID: 31254407
BACKGROUND: The aim of our study was to assess clinico-pathological and biochemical parameters of Type 1 Gastric Neuroendocrine Neoplasms (GNEN1) with respect to tumours propensity for recurrence and metastasis. ...Many patients though will experience local recurren …
BACKGROUND: The aim of our study was to assess clinico-pathological and biochemical parameters of Type 1 Gastric Neuroendocrine …
Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
Milione M, Miceli R, Barretta F, Pellegrinelli A, Spaggiari P, Tagliabue G, Centonze G, Paolino C, Mangogna A, Kankava K, Pusceddu S, Giacomelli L, Corti A, Cotsoglou C, Mazzaferro V, Sozzi G, de Braud F, Pruneri G, Anichini A. Milione M, et al. J Pathol Clin Res. 2019 Oct;5(4):217-226. doi: 10.1002/cjp2.135. Epub 2019 Jul 9. J Pathol Clin Res. 2019. PMID: 31136102 Free PMC article.
Microenvironment-related immune and inflammatory markers, when combined with established Ki-67 and morphology parameters, can improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs). ...From our analysis, G1/G2 versus G3 …
Microenvironment-related immune and inflammatory markers, when combined with established Ki-67 and morphology parameters, can improve progno …
Surgical treatment and prognosis of gastric neuroendocrine neoplasms: a single-center experience.
Shen C, Chen H, Chen H, Yin Y, Han L, Chen J, Tang S, Yin X, Zhou Z, Zhang B, Chen Z. Shen C, et al. BMC Gastroenterol. 2016 Sep 9;16(1):111. doi: 10.1186/s12876-016-0505-5. BMC Gastroenterol. 2016. PMID: 27613657 Free PMC article.
BACKGROUND: Gastric neuroendocrine neoplasms (G-NENs) are uncommon, and data on their management is limited. ...Twenty-five patients underwent endoscopic resection, while 110 patients underwent open/laparoscopic surgery. Thirty-nine patients had neuroendocrine …
BACKGROUND: Gastric neuroendocrine neoplasms (G-NENs) are uncommon, and data on their management is limited. ...Twenty-five pa …
Expression of LAT1 and 4F2hc in Gastroenteropancreatic Neuroendocrine Neoplasms.
Horita Y, Kaira K, Kawasaki T, Mihara Y, Sakuramoto S, Yamaguchi S, Okamoto K, Ryozawa S, Kanai Y, Yasuda M, Hamaguchi T. Horita Y, et al. In Vivo. 2021 Jul-Aug;35(4):2425-2432. doi: 10.21873/invivo.12520. In Vivo. 2021. PMID: 34182526 Free PMC article.
We evaluated LAT1 and 4F2hc expression by immunohistochemistry, and examined their clinical significance. RESULTS: No statistically significant associations were observed between LAT1 expression and the different NENs. Expression of 4F2hc was significantly different betwee …
We evaluated LAT1 and 4F2hc expression by immunohistochemistry, and examined their clinical significance. RESULTS: No statistically signific …
Tumour type and size are prognostic factors in gastric neuroendocrine neoplasia: A multicentre retrospective study.
Panzuto F, Campana D, Massironi S, Faggiano A, Rinzivillo M, Lamberti G, Sciola V, Lahner E, Manuzzi L, Colao A, Annibale B. Panzuto F, et al. Dig Liver Dis. 2019 Oct;51(10):1456-1460. doi: 10.1016/j.dld.2019.04.016. Epub 2019 Jun 5. Dig Liver Dis. 2019. PMID: 31175013
BACKGROUND: Gastric neuroendocrine neoplasias (gNEN) are defined as type I if associated with atrophic body gastritis and type III when tumour is sporadic. ...Among type I, 103 were G1 (75.2%) and 34 (24.8%) were G2. In type III group, 8 were G1 (42.1%), 10 w …
BACKGROUND: Gastric neuroendocrine neoplasias (gNEN) are defined as type I if associated with atrophic body gastritis and type …
Clinical outcomes of gastroduodenal neuroendocrine tumors according to their WHO grade: A single-institutional retrospective analysis.
Ryu DG, Kim SJ, Choi CW, Kang DH, Kim HW, Park SB, Nam HS, Lee SH, Hwang SH. Ryu DG, et al. Medicine (Baltimore). 2022 Sep 16;101(37):e30397. doi: 10.1097/MD.0000000000030397. Medicine (Baltimore). 2022. PMID: 36123854 Free PMC article.
The management of gastroduodenal neuroendocrine tumor (NET) has been controversial between radical surgical resection and local excision including endoscopic resection. ...All G3 gastroduodenal NETs showed metastasis (one lymph node metastasis and 3 hepatic metastas …
The management of gastroduodenal neuroendocrine tumor (NET) has been controversial between radical surgical resection and loca …
Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms.
La Rosa S, Inzani F, Vanoli A, Klersy C, Dainese L, Rindi G, Capella C, Bordi C, Solcia E. La Rosa S, et al. Hum Pathol. 2011 Oct;42(10):1373-84. doi: 10.1016/j.humpath.2011.01.018. Epub 2011 May 4. Hum Pathol. 2011. PMID: 21531442
Fifty-one grade 3 neuroendocrine carcinomas and 15 mixed endocrine-exocrine carcinomas of poor outcome were separated from 143 neuroendocrine tumors, including 132 G1 or G2 enterochromaffin-like (ECL) cell neoplasms and 11 G1 gastrin-cell, somatostatin …
Fifty-one grade 3 neuroendocrine carcinomas and 15 mixed endocrine-exocrine carcinomas of poor outcome were separated from 143 neu …
61 results